Last reviewed · How we verify
A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin
Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)
Details
| Lead sponsor | Allergan |
|---|---|
| Status | COMPLETED |
| Enrolment | 50 |
| Start date | 2009-01 |
| Completion | 2009-12 |
Conditions
- Ocular Hypertension
Interventions
- Loteprednol etabonate ophthalmic suspension 0.5%
- Loteprednol etabonate (0.5%) and tobramycin (0.3%).
Primary outcomes
- Mean Elevated Intraocular Pressure (IOP) During Treatment — 55 days
Mean elevated IOP during treatment. IOP is a measurement of the fluid pressure inside the eye. IOP was recorded any time an elevation of IOP (increase of 5 mmHg or more) occurred while using study treatment. The median duration of treatment at the time of observed IOP elevation was 55 days.
Countries
United States